Drug Trial Radar · NCT03598790
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,353
Actual
Start
Sep 5, 2018
Primary completion
Nov 14, 2023
Study completion Nov 14, 2023
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jul 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
Conditions
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Locations
189 sites in 13 countries. Site status is shown where the registry gives one.
Ps0014 957
Glendale, Arizona
Ps0014 946
Phoenix, Arizona
Ps0014 910
Bakersfield, California
Ps0014 927
Los Angeles, California
Ps0014 919
San Diego, California
Ps0014 955
San Diego, California
Ps0014 943
San Luis Obispo, California
Ps0014 967
Santa Monica, California
Ps0014 934
Washington D.C., District of Columbia
Ps0014 909
Boynton Beach, Florida
Ps0014 912
Coral Gables, Florida
Ps0014 928
Fort Myers, Florida
Ps0014 906
Hollywood, Florida
Ps0014 907
Miami, Florida
Ps0014 903
Ocala, Florida
Ps0014 921
Ormond Beach, Florida
Ps0014 936
Tampa, Florida
Ps0014 941
Alpharetta, Georgia
Ps0014 954
Skokie, Illinois
Ps0014 911
Plainfield, Indiana
Ps0014 900
West Des Moines, Iowa
Ps0014 905
Overland Park, Kansas
Ps0014 962
Owensboro, Kentucky
Ps0014 922
Baton Rouge, Louisiana
Ps0014 944
New Orleans, Louisiana
Ps0014 940
Beverly, Massachusetts
Ps0014 925
Brighton, Massachusetts
Ps0014 917
Troy, Michigan
Ps0014 915
Clayton, Missouri
Ps0014 958
Omaha, Nebraska
Ps0014 901
Portsmouth, New Hampshire
Ps0014 908
East Windsor, New Jersey
Ps0014 956
Verona, New Jersey
Ps0014 947
Buffalo, New York
Ps0014 965
Kew Gardens, New York
Ps0014 913
New York, New York
Ps0014 963
Rochester, New York
Ps0014 961
Rocky Mount, North Carolina
Ps0014 932
Oklahoma City, Oklahoma
Ps0014 920
Portland, Oregon
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.